George Makiev

Mr. George Makiev

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2026 in Cancers
Verified
Journal Article
Open access
PDF file
GMGeorge Makiev
George Makiev
ISIgor Samoylenko
Igor Samoylenko
VNValeria V. Nazarova
Valeria V. Nazarova
ZMZakhra Magomedova
Zakhra Magomedova
ATAlexey Tryakin
Alexey Tryakin
TGTigran G. Gevorkyan
Tigran G. Gevorkyan
Background: The persistently low 5-year survival rate for pancreatic cancer (PC) underscores the critical need for early detection. However, population-wide screening remains impractical. Artificial Intelligence (AI) models using electronic health record (EHR) data offer a promising avenue for pre-symptomatic risk stratification. Objective: To systematically review and meta-analyze the performance of AI models for PC prediction based exclusively on structured EHR data. Methods: We systematically searched PubMed, MedRxiv, BioRxiv, and Google Scholar (2010–2025). Inclusion criteria encompassed studies using EHR-derived data (excluding imaging/genomics), applying AI for PC prediction, reporting AUC, and including a non-cancer cohort. Two reviewers independently extracted data. Random-effects meta-analysis was performed for AUC, sensitivity (Se), and specificity (Sp) using R software version 4.5.1. Heterogeneity was assessed using I2 statistics and publication bias was evaluated. Results: Of 946 screened records, 19 studies met the inclusion criteria. The pooled AUC across all models was 0.785 (95% CI: 0.759–0.810), indicating good overall discriminatory ability. Neural Network (NN) models demonstrated a statistically significantly higher pooled AUC (0.826) compared to Logistic Regression (LogReg, 0.799), Random Forests (RF, 0.762), and XGBoost (XGB, 0.779) (all p < 0.001). In analyses with sufficient data, models like Light Gradient Boosting (LGB) showed superior Se and Sp (99% and 98.7%, respectively) compared to NNs and LogReg, though based on limited studies. Meta-analysis of Se and Sp revealed extreme heterogeneity (I2 ≥ 99.9%), and the positive predictive values (PPVs) reported across studies were consistently low (often < 1%), reflecting the challenge of screening a low-prevalence disease. Conclusions: AI models using EHR data show significant promise for early PC detection, with NNs achieving the highest pooled AUC. However, high heterogeneity and typically low PPV highlight the need for standardized methodologies and a targeted risk-stratification approach rather than general population screening. Future prospective validation and integration into clinical decision-support systems are essential.

15 March 2026 in Surgery and Oncology
Verified
Journal Article
Open access
GNGrigoriy M. Naydin
Grigoriy M. Naydin
DBD. А. Barsova
D. А. Barsova
FMFedor Moiseenko
Fedor Moiseenko
ARA. B. Rays
A. B. Rays
MFMikhail Fedyanin
Mikhail Fedyanin
ATAlexey Tryakin
Alexey Tryakin
Introduction. Therapeutic options for 3rd-line treatment of metastatic colorectal cancer (mCRC) include chemotherapy retreatment with previously used regimens and regorafenib. Due to the lack of phase III prospective studies and conflicting retrospective results, we performed a comparative analysis of the efficacy and safety of chemotherapy ± targeted therapy retreatment versus regorafenib in a large patient cohort. Materials and methods. The study included mCRC patients from 4 oncology centers in the Russian Federation treated between 2010 and 2021 who received 3rd-line therapy either with chemotherapy ± targeted agents (epidermal growth factor receptor or vascular endothelial growth factor antibodies) (CTT group) or with regorafenib. The primary endpoint was 9-month overall survival (OS); secondary endpoints were progression-free survival (PFS), objective response rate (ORR) and toxicity. Univariable and multivariable analyses were conducted to identify prognostic factors. Results. A total of 334 patients were included. Median follow-up was 30.3 months (95 % confidence interval (CI) 26.0–34.5) in the CTT group and 23.8 months in the regorafenib group. The groups differed in several baseline characteristics: primary tumor resection was performed more frequently (76.1 % versus 67.6 %; p = 0.088) and ECOG 0 status was more common (25.2 % versus 14.2 %; p = 0.006) in the CTT group. Patients treated with regorafenib more frequently had elevated carcinoembryonic antigen ≥50 ng / mL (45.3 % versus 65.3 %; p 0.001) and indolent disease course ≥20 months (64.3 % versus 49.1 %; p = 0.005), while a «treatment-free interval» ≥6 months after oxaliplatin or irinotecan was observed less frequently (68.1 % versus 43.3 %; p 0.001). Chemotherapy retreatment demonstrated a statistically significant advantage in median OS (18.1 months versus 10.2 months; hazard ratio (HR) 0.51; 95 % CI 0.39–0.67; p 0.0001) and PFS (6.0 month versus 2.8 months; HR 0.54; 95 % CI 0.43–0.67; p 0.0001). ORR was 6.1 % in the CTT group compared to 0.6 % in the regorafenib group. In multivariable analysis, unfavorable prognostic factors were worse ECOG status (ECOG 1: HR 1.77; p = 0.002; ECOG 2: HR 2.56; p = 0.001), right-sided primary tumor location (HR 1.98; p 0.001), presence of ≥2 liver metastases (HR 1.52; p = 0.021), absence of radical resection of the primary tumor (HR 1.91, 95 % CI 1.32–2.78; p = 0.001), shorter interval between 1st-line and 3rd-line therapy (a longer course 20 months correlated with better prognosis: HR 1.38, 95 % CI 1.04–1.85; p = 0.028), and carcinoembryonic antigen ≥50 ng / mL (HR 1.38, 95 % CI 1.04–1.82; p = 0.026). Based on these factors, a prognostic model was created that identifies favorable (median OS 19.4 months), intermediate (median OS 13.0 months), and poor (median OS 6.6 months) risk groups. The C-index was 0.698 (standard error 0.02). Conclusion. Chemotherapy retreatment showed superiority over regorafenib in 3rd-line treatment of mCRC. Its higher efficacy was confirmed across all prognostic subgroups. Predictive analysis did not identify any subgroup with advantage from regorafenib therapy.

8 September 2024 in Medical alphabet
Verified
Journal Article
Closed access
PDF file
DGD. A. Gavrilova
D. A. Gavrilova
NBN. S. Besova
N. S. Besova
EOE. S. Obarevich
E. S. Obarevich
GMGeorge Makiev
George Makiev
ARA. B. Rays
A. B. Rays
ATAlexey Tryakin
Alexey Tryakin
Given the poor treatment outcomes of disseminated gastric cancer (dGC), the search for new drug treatment options remains a pressing issue. According to some literature, the use of a chemotherapeutic triplet in the first line improves patient survival rates. An interim analysis of a prospective randomised phase III trial examines the comparison of the chemotherapeutic regimens mFOLFIRINOX and mFOLFOX6 in the first-line treatment of HER2-negative gastric adenocarcinoma. In this interim analysis, significant differences between patients receiving mFOLFIRINOX or mFOLFOX6 regarding the primary endpoint of mVBP were detected only in the group of patients with dissemination to the retroperitoneal lymph nodes. Overall, based on the results of this work, it can be concluded that the majority of patients do not require intensification of first-line treatment for gastric adenocarcinoma in the form of mFOLFIRINOX chemotherapy. However, final conclusions on the efficacy of the triple combination can only be drawn upon completion of the entire study.

26 July 2025 in Medical alphabet
Verified
Journal Article
Closed access
PDF file
AKA. Yu. Kashcheeva
A. Yu. Kashcheeva
APA. N. Polyakov
A. N. Polyakov
GMGeorge Makiev
George Makiev
DKD. M. Kantieva
D. M. Kantieva
YCYа. E. Chikhareva
Yа. E. Chikhareva
ЯЧЯ. Е. Чихарева
Я. Е. Чихарева
Pancreatic cancer (PC) remains one of the most aggressive malignancies with poor prognosis, particularly in locally advanced and metastatic forms. Germline BRCA1/2 mutations, found in approximately 5 % of PC patients, are associated with increased sensitivity to platinum-based chemotherapy (CT) and PARP inhibitor therapy. This article presents a clinical case of successful combined treatment for locally advanced BRCA1-associated PC. The reported case demonstrates the efficacy of a comprehensive approach incorporating platinum-based CT, irreversible electroporation (IRE), pancreatic resection, stereotactic radiotherapy (RT), and PARP inhibitor targeted therapy in BRCA1-associated PC. The study highlights the crucial importance of molecular genetic testing at initial diagnosis for optimal treatment strategy selection. The findings confirm both the efficacy and safety of prolonged olaparib administration, warranting further investigation of this therapeutic approach in clinical trials.

9 November 2025 in Medical alphabet
Verified
Journal Article
Open access
PDF file
GMGeorge Makiev
George Makiev
ADA. B. Dopchut
A. B. Dopchut
RAR. Sh. Abdulayeva
R. Sh. Abdulayeva
GNG. M. Naydin
G. M. Naydin
EOE. S Obarevich
E. S Obarevich
МФМ. Ю. Федянин
М. Ю. Федянин
Objective : to evaluate prognostic factors in patients with metastatic colorectal cancer (mCRC) and isolated liver metastases, and to analyze the role of systemic therapy in achieving resectability and the impact of surgical treatment on survival outcomes. Materials and methods . A retrospective study of 371 patients with mCRC and initially unresectable isolated liver metastases. Resectability was assessed by a multidisciplinary tumor board. Patients received systemic chemotherapy with targeted agents (bevacizumab or anti-EGFR). Progression-free survival (PFS), conversion rates, and prognostic factors were analyzed using univariate and multivariate methods. Results . The conversion rate to resectability was 60.1 % (potentially resectable metastases) and 25.9 % (unresectable metastases). Median PFS was 11.3 months (12.7 months for resectable vs. 10.5 months for unresectable). R 0 resection was achieved in 78.8 % and 72.4 % of patients, respectively. Multivariate analysis identified favorable prognostic factors: primary tumor resection and disease stabilization/partial response to therapy. Poor prognostic factors included unresectable metastases and limited/non-countable metastatic lesions. Conclusions . A combined systemic and surgical approach improves survival in mCRC patients, particularly after successful conversion of initially unresectable metastases.

21 April 2026 in Malignant tumours
Verified
Journal Article
Open access
PDF file
KMK. I. Murzakhanova
K. I. Murzakhanova
OKO. A. Kuznetsova
O. A. Kuznetsova
GMGeorge Makiev
George Makiev
DLD. O. Lipatov
D. O. Lipatov
YEYu. V. Eroshin
Yu. V. Eroshin
ATAlexey Tryakin
Alexey Tryakin
Objective : to present and analyze the clinical treatment outcomes of patients with RAS-mutated metastatic colorectal cancer based on two case reports, assessing the efficacy of systemic therapy regimens, and demonstrating factors influencing treatment strategy and tumor response. These cases demonstrate the need for new markers and a personalized approach to therapy in patients with colorectal cancer. These observations were compared with current literature data, demonstrating the practical value of an individualized approach to treating patients with RAS-mutated metastatic colorectal cancer.